Adenosine triphosphate

ApprovedSmall molecule

EEgyptian International Pharmaceutical Industries Co

Adenosine triphosphate is one of 118 small molecule programs targeting Alzheimer disease. It is currently in Approved.

Indications

Total Trials

Active Trials

117

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer DiseaseActive, not recruiting

Paroxysmal Atrial FibrillationActive, not recruiting

Diabetic PolyneuropathyActive, not recruiting

Chronic CoughActive, not recruiting

Alzheimer DiseasePhase 2

Active, not recruiting

Paroxysmal Atrial FibrillationPreclinical

Active, not recruiting

Diabetic PolyneuropathyApproved

Active, not recruiting

Chronic CoughPreclinical

Active, not recruiting

Competition

Competitive Landscape

171 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Kisunla

Eli Lilly

Phase 3

2 2

Tirazone

Karxt

3 4

Karx-EC

Bristol-Myers Squibb

Phase 3

2 5

Adenosine triphosphate

EEgyptian International Pharmaceutical Industries Co

Approved

1 6

Aquasol E

NNational Eye Institute (NEI)

Aricept

2 8

Naproxen Sodium

Namenda

1 10

Exelon

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Post-ApprovalNot yet recruiting

Diabetic Polyneuropathy

NCT07296354

Clinical

Trials by Indication[1]

Paroxysmal atrial fibrillation1 trial

A Time-to-effect Based Dosing Strategy in Cryoballoon Ablation of Patients With Paroxysmal Atrial Fibrillation

Completed·FFundación para la Investigación del Hospital Clínico de Valencia·N/A·NCT02789358·140 enrolled

Diabetic Polyneuropathy1 trial

Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy

Not yet recruiting·EEgyptian International Pharmaceutical Industries Co·Phase 4·NCT07296354·200 enrolled

Alzheimer disease1 trial

ATP in Alzheimer Disease

Completed·SSara Varea·Phase 2·NCT02279511·20 enrolled

Vasodilation1 trial

Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

Completed·—·Phase 1·NCT03738943·9 enrolled

Exercise Training1 trial

Role of Acetylcholine in Blood Flow Regulation in Healthy Adults: Effects of Age and Exercise Training

Withdrawn·—·Phase 1·NCT03972683

2 more indications

Patients With Advanced Solid Tumors1 trial

Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00014248

Chronic Cough1 trial

Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients

Completed·SStuart Mazzone·N/A·NCT03722849·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Adenosine triphosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adenosine triphosphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adenosine triphosphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Egyptian International Pharmaceutical Industries Co company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: EEgyptian International Pharmaceutical Industries Co

Adenosine triphosphate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Paroxysmal atrial fibrillation1 trial

Diabetic Polyneuropathy1 trial

Alzheimer disease1 trial

Vasodilation1 trial

Exercise Training1 trial

Patients With Advanced Solid Tumors1 trial

Chronic Cough1 trial

References

Drug Info

Quick Facts

Related News